Lola Cook

Lola Cook

Auto-generated profile, based on publicly available information

Lola Cook

Indiana University School of Medicine Medical and Molecular Genetics Indianapolis Indiana USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2021 in Journal of Genetic Counseling
Verified
Journal Article
Closed access
PDF file
NDNoelle R. Danylchuk
Noelle R. Danylchuk
LCLola Cook
Lola Cook
KSKate P. Shane‐Carson
Kate P. Shane‐Carson
CCCara N. Cacioppo
Cara N. Cacioppo
MHMelanie W. Hardy
Melanie W. Hardy
JMJennifer Malinowski
Jennifer Malinowski

1 February 2021 in Neurology Clinical Practice
Verified
Journal Article
Closed access
PDF file
LCLola Cook
Lola Cook
JSJeanine Schulze
Jeanine Schulze
CKCatherine Kopil
Catherine Kopil
THTara Hastings
Tara Hastings
ANAnna Naito
Anna Naito
TFTatiana Foroud
Tatiana Foroud
Purpose of Review With the advent of precision medicine and demand for genomic testing information, we may question whether it is time to offer genetic testing to our patients with Parkinson disease (PD). This review updates the current genetic landscape of PD, describes what genetic testing may offer, provides strategies for evaluating whom to test, and provides resources for the busy clinician. Recent Findings Patients with PD and their relatives, in various settings, have expressed an interest in learning their PD genetic status; however, physicians may be hesitant to widely offer testing due to the perceived low clinical utility of PD genetic test results. The rise of clinical trials available for patients with gene-specific PD and emerging information on genotype-phenotype correlations are starting to shift this discussion about testing. Summary By learning more about the various genetic testing options for PD and utility of results for patients and their care, clinicians may become more comfortable with widespread PD genetic testing in the research and clinical setting.

27 June 2023 in Movement Disorders
Verified
Journal Article
Open access
GPGian Pal
Gian Pal
LCLola Cook
Lola Cook
JSJeanine Schulze
Jeanine Schulze
JVJennifer Verbrugge
Jennifer Verbrugge
RARoy N. Alcalay
Roy N. Alcalay
CKChristine Klein
Christine Klein
Genetic testing for persons with Parkinson's disease is becoming increasingly common. Significant gains have been made regarding genetic testing methods, and testing is becoming more readily available in clinical, research, and direct‐to‐consumer settings. Although the potential utility of clinical testing is expanding, there are currently no proven gene‐targeted therapies, but clinical trials are underway. Furthermore, genetic testing practices vary widely, as do knowledge and attitudes of relevant stakeholders. The specter of testing mandates financial, ethical, and physician engagement, and there is a need for guidelines to help navigate the myriad of challenges. However, to develop guidelines, gaps and controversies need to be clearly identified and analyzed. To this end, we first reviewed recent literature and subsequently identified gaps and controversies, some of which were partially addressed in the literature, but many of which are not well delineated or researched. Key gaps and controversies include: (1) Is genetic testing appropriate in symptomatic and asymptomatic individuals without medical actionability? (2) How, if at all, should testing vary based on ethnicity? (3) What are the long‐term outcomes of consumer‐ and research‐based genetic testing in presymptomatic PD? (4) What resources are needed for clinical genetic testing, and how is this impacted by models of care and cost‐benefit considerations? Addressing these issues will help facilitate the development of consensus and guidelines regarding the approach and access to genetic testing and counseling. This is also needed to guide a multidisciplinary approach that accounts for cultural, geographic, and socioeconomic factors in developing testing guidelines. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

8 June 2023 in Genetics in Medicine
Verified
Journal Article
Open access
LCLola Cook
Lola Cook
JVJennifer Verbrugge
Jennifer Verbrugge
TSTae-Hwi Schwantes-An
Tae-Hwi Schwantes-An
JSJeanine Schulze
Jeanine Schulze
JBJames C. Beck
James C. Beck
RARoy N. Alcalay
Roy N. Alcalay
To evaluate the feasibility and impact of offering genetic testing and counseling to patients with Parkinson's disease (PD), with the potential to enroll in gene-targeted clinical trials and improve clinical care. A multicenter, exploratory pilot study at 7 academic hospital sites in the United States tracked enrollment and randomized participants to receive results and genetic counseling at local sites or by genetic counselors, remotely. Follow-up surveys measured participant/provider satisfaction, knowledge, and psychological impact. From September 5, 2019 to January 4, 2021, 620 participants were enrolled and 387 completed outcome surveys. There were no significant differences in outcomes between local and remote sites, with both arms reporting high knowledge and satisfaction scores (>80%). Notably, 16% of those tested had reportable PD gene variants (pathogenic/likely pathogenic/risk allele). Local clinicians, as well as genetic counselors, with educational support as needed, can effectively return genetic results for PD as we observed favorable outcome measures in both groups. Increasing access to PD genetic testing and counseling is urgent; this can inform future efforts to integrate genetic testing and counseling into clinical care for all those with PD.

19 October 2021 in Parkinsonism & Related Disorders
Verified
Journal Article
Open access
LCLola Cook
Lola Cook
JSJeanine Schulze
Jeanine Schulze
JVJennifer Verbrugge
Jennifer Verbrugge
JBJames C. Beck
James C. Beck
KMKaren S. Marder
Karen S. Marder
VBVincenzo Bonifati
Vincenzo Bonifati
There have been no specific guidelines regarding which genes should be tested in the clinical setting for PD or parkinsonism. We evaluated the types of clinical genetic testing offered for Parkinson’s disease (PD) as the first step of our gene curation. The National Institutes of Health (NIH) Genetic Testing Registry (GTR) was queried on 12/7/2020 to identify current commercial PD genetic test offerings by clinical laboratories, internationally. We identified 502 unique clinical genetic tests for PD, from 28 Clinical Laboratory Improvement Amendments (CLIA)-approved clinical laboratories. These included 11 diagnostic PD panels. The panels were notable for their differences in size, ranging from 5 to 62 genes. Five genes for variant query were included in all panels (SNCA, PRKN, PINK-1, PARK7 (DJ1), and LRRK2). Notably, the addition of the VPS35 and GBA genes was variable. Panel size differences stemmed from inclusion of genes linked to atypical parkinsonism and dystonia disorders, and genes in which the link to PD causation is controversial. There is an urgent need for expert opinion regarding which genes should be included in a commercial laboratory multi-gene panel for PD.

8 March 2021 in Current Neurology and Neuroscience Reports
Verified
Journal Article
Closed access
PDF file
LCLola Cook
Lola Cook
JSJeanine Schulze
Jeanine Schulze
ANAnna Naito
Anna Naito
RARoy N. Alcalay
Roy N. Alcalay